Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Vascular Medicine (London, England)|February 28, 2022
Implementation of supervised exercise therapy in a veteran population with symptomatic claudicationS Elissa Altin, Marabel D Schneider, Helen Parise, et al.
Diabetes Technology & Therapeutics|January 3, 2006
Evaluation of a continuous glucose monitoring system for use in veterinary medicineCharles E Wiedmeyer, Philip J Johnson, Leah A Cohn, et al.
The Journal of Infectious Diseases|June 1, 1997
Diagnosis of perinatal human immunodeficiency virus infection by polymerase chain reaction and p24 antigen detection after immune complex dissociation in an urban community hospitalS Nesheim, F Lee, M L Kalish, et al.
Substance Use & Misuse|December 18, 2003
Prenatal cocaine exposure and infant performance on the Brazelton Neonatal Behavioral Assessment ScaleBarbara J Myers, Kathryn S Dawson, Gena C Britt, et al.
The Journal of Experimental Medicine|January 31, 1998
The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosolC A Mosse, L Meadows, C J Luckey, et al.
Anticancer Research|January 2, 2010
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumorsElizabeth Dugan, Roxanne Truax, Kellen L Meadows, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
International Journal of Psychiatry in Medicine|August 18, 2023
Adverse childhood experiences and early initiation of substance use: A survival analysisAmy L Meadows, Justin C Strickland, S Maela Hyder, et al.
IEEE Journal of Biomedical and Health Informatics|April 10, 2023
A Comparative Effectiveness Study on Opioid Use Disorder Prediction Using Artificial Intelligence and Existing Risk ModelsSajjad Fouladvand, Jeffery Talbert, Linda P Dwoskin, et al.
Anticancer Research|June 10, 2010
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsElizabeth Dugan, Roxanne Truax, Kellen L Meadows, et al.
Pageof 17